Pharmacogenomics Market (By Technology: DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry; By Applications: Drug Discovery, Pain management, Neurology, Oncology, Drug Discovery, Cardiovascular diseases, Infectious diseases, Psychiatry; By End User: Hospitals, Clinics, Research institute, Medical, academic institute; By Distribution Channel)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global pharmacogenomics market size was valued at USD 15.00 billion in 2022 and it is expected to reach around USD 36.17 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 9.2% during the forecast period 2023 to 2032.

Pharmacogenomics Market Size 2023 To 2032

Key Takeaways:

  • By application, oncology segment has accounted highest revenue share of over 30.3% in 2022
  • By region, North America held 41.4% revenue share in 2022.
  • By technology, the polymerase chain reaction segment hit market share of around 37.0% in 2022.

Pharmacogenomics Market Report Scope

 Report Coverage  Details
Market Size in 2023 USD 15.00 Billion
Market Size by 2032 USD 36.17 Billion
Growth Rate From 2023 to 2032 CAGR of 9.2%
Base Year 2022
Forecast Period 2023-2032
Segments Covered Technology, Applications, End User, Distribution Channel and Geography
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Abbott (US), Bayer AG (Germany), Allergan (Ireland), AbbVie Inc (US), GmBH (Germany), Teva Pharmaceutical Industries ltd (India), Natco Pharma Limited (India), Lupin (India), Sun Pharmaceutical Industries ltd (India), Merck & Co Inc (Germany), Eli Lilly and Company (US), Squiib Company (US), Novartis AG (Switzerland), Mylan N.V. (US), Ferndale Pharma Group Inc, (US), f. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (US) and Takeda Pharmaceutical Industries ltd (Japan)

 

Pharmacogenomics Market Trends

This section covers the major market trends shaping the Pharmacogenomics Market according to our research experts: 

Drug Discovery Segment is Expected to Occupy a Significant Share in the Pharmacogenomics market Over the Forecast Period

Drug discovery is a process that aims at identifying a compound that helps in treating and curing diseases therapeutically. Typically, a drug discovery effort addresses a biological target that plays a role in developing the disease or starts from a molecule with interesting biological activities. In clinical studies, pharmacogenetic testing can be used to group people according to their genotype, reflecting how well they can metabolize drugs. The clinical trials that result in adverse drug reactions are avoided. This can also reduce the attrition of drug compounds.

Factors such as the rising incidence of cancer and other chronic diseases, increasing R&D activities for developing potential new drugs for these diseases, and an increase in demand for precision medicine are expected to enhance the segment's growth during the forecast period. Additionally, pharmacogenomics improves the drug's efficacy and reduces the chances of adverse effects. Hence this factor is expected to play a significant role in the growth of the studied segment. For instance, according to a research study published by Drug Metabolism Reviews in April 2021, pharmacogenomics can assist drug researchers in identifying drug responders and non-responders as well as people at risk of ADRs, with the main objective of accelerating medication development and preventing drug failures. This can be accomplished by incorporating genomic data into various stages of drug discovery and development, starting with the identification and validation of biological targets and moving on to patient recruitment for clinical trials.

The increasing investment in drug discovery processes and development activities will further increase the adoption of pharmacogenomics technology which is anticipated to have a significant and positive impact on the drug discovery segment in the pharmacogenomics market. According to the 2022 annual report of Eli Lilly and Company, their research and development expenditure increased to USD 7,025.9 million in 2021 and it has increased over the years owing to the high investment in the new drug discovery and development activities.

Therefore, owing to factors such as increasing investment in drug discovery processes and development activities and rising incidence of cancer and other chronic diseases, the drug discovery segment is expected to hold a significant share in the pharmacogenomics market during the forecast period.

Key Market Drivers

  • Increasing number of disorders - Increasing population with increasing number of chronic disorders such as gastrointestinal disorders, inflammatory bowel diseases, cancer, HIV, AIDS, and many more diseases led to development of advance technologies and efficient drug therapy with good therapeutic response and increased demands from the health professionals for the effective developed drug and advance treatments to increase the safety of the individuals.
  • Infrastructure development - Increasing number of developed technologies and medical devices with new equipment’s in health care centers along with newly developed infrastructure which contributes for the growth of the pharmacogenomics market rate to a greater extent
  • Research and development - Market Players involved in the research and development process to introduce new drug development with higher efficiency and increased therapeutic index with no adverse effects of the drug to the individuals. Which expands the pharmacogenomics market growth during the forecast period with new advanced technologies and effective drug therapies available.

Market Challenges 

  • Increased costing of the treatment - Increased advanced developed methods with new drug developments with higher affectivity to the genomes and increased research and development by the market players emerged to the increased costing of the drug therapies. Which may be the biggest challenge to increase the market rate of pharmacogenomics.
  • Underdeveloped Infrastructure facilities - The old infrastructure health care center having the developed advanced technologies developed in underdeveloped health care centers which will affect the consumption of the drugs. Utmost important to develop the infrastructures with wide developments required in health centers for patients safety or may hamper the growth of the market during the forecast period.
  • Lack of Skill Work - Increased developments in pharmacogenomics with improved drug efficiency and no adverse drug reactions. New developments and methods with new skills.  Lack of skill among the people to perform the procedures may decrease the pharmacogenomics market rate. Health professionals with required skills are utmost important to perform the therapies with the aim of patients safety.

Market Opportunities

  • Growing Disorders - Growing prevalence of chronic disorders among the individuals such as cancer, HIV, AIDS, tuberculosis, gastrointestinal disorders, respiratory disorder and many more. Which led to increase demand of the newly developed effective drug therapies may enhance the pharmacogenomics market rate. Improved technologies and methods developed in pharmacogenomics help to boost the market growth to a greater extent.
  • Government Integration - Increased support from the government to develop the drug therapies along with newly developed medical devices with higher efficiency of the drug to the different genomes and to increase the research process of developments. Government support with rules and regulations imposed with reimbursement policies developed for the citizens.
  • Key Market Players - The key market players involved in introducing the newly developed drug therapies with high efficiency and increased safety have help to boost the market growth to a higher extent, increased development and research process for new drug development process have increased the market revenue share with increased demand during the forecast period.

Recent Development

  • In the year2022 March, in community pharmacy Day-Lewis was the first to introduce the private pharmacogenomics testing service.

Key market players

Some of the prominent players in the Pharmacogenomics Market include:

  • Abbott (US)
  • Bayer AG (Germany)
  • Allergan (Ireland)
  • AbbVie Inc (US)
  • GmBH (Germany)
  • Teva Pharmaceutical Industries ltd (India)
  • Natco Pharma Limited (India)
  • Lupin (India)
  • Sun Pharmaceutical Industries ltd (India)
  • Merck & Co Inc (Germany)
  • Eli Lilly and Company (US)
  • Squiib Company (US)
  • Novartis AG (Switzerland)
  • Mylan N.V. (US)
  • Ferndale Pharma Group Inc, (US)
  • f. Hoffmann-La Roche Ltd (Switzerland)
  • Pfizer Inc (US)
  • Takeda Pharmaceutical Industries ltd (Japan)

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2032. For this study, Nova one advisor, Inc. has segmented the global Pharmacogenomics market.

By Technology

  • DNA Sequencing
  • Microarray
  • Polymerase Chain Reaction
  • Electrophoresis
  • Mass Spectrometry

By Applications

  • Drug Discovery
  • Pain management
  • Neurology
  • Oncology
  • Cardiovascular diseases
  • Infectious diseases
  • Psychiatry
  • Others

By End User 

  • Hospitals
  • Clinics
  • Research institute
  • Medical, academic institute

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global pharmacogenomics market size was reached at USD 15.00 billion in 2022 and it is projected to hit around USD 36.17 billion by 2032.

The global pharmacogenomics market is growing at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2032.

The North America region has accounted for the largest Pharmacogenomics market share in 2022.

Abbott (US), Bayer AG (Germany), Allergan (Ireland), AbbVie Inc (US), GmBH (Germany), Teva Pharmaceutical Industries ltd (India), Natco Pharma Limited (India), Lupin (India), Sun Pharmaceutical Industries ltd (India), Merck & Co Inc (Germany), Eli Lilly and Company (US), Squiib Company (US), Novartis AG (Switzerland), Mylan N.V. (US), Ferndale Pharma Group Inc, (US), f. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (US) and Takeda Pharmaceutical Industries ltd (Japan)

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmacogenomics Market 

5.1. COVID-19 Landscape: Pharmacogenomics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmacogenomics Market, By Technology

8.1. Pharmacogenomics Market, by Technology, 2023-2032

8.1.1. DNA Sequencing

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Microarray

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Polymerase Chain Reaction

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Electrophoresis

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Mass Spectrometry

8.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Pharmacogenomics Market, By Applications

9.1. Pharmacogenomics Market, by Applications e, 2023-2032

9.1.1. Drug Discovery

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Pain management

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Neurology

9.1.3.1. Market Revenue and Forecast (2021-2032)

9.1.4. Oncology

9.1.4.1. Market Revenue and Forecast (2021-2032)

9.1.5. Cardiovascular diseases

9.1.5.1. Market Revenue and Forecast (2021-2032)

9.1.6. Infectious diseases

9.1.6.1. Market Revenue and Forecast (2021-2032)

9.1.7. Psychiatry

9.1.7.1. Market Revenue and Forecast (2021-2032)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Pharmacogenomics Market, By End User 

10.1. Pharmacogenomics Market, by End User, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Clinics

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Research institute

10.1.3.1. Market Revenue and Forecast (2021-2032)

10.1.4. Medical, academic institute

10.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Pharmacogenomics Market, By Distribution Channel 

11.1. Pharmacogenomics Market, by Distribution Channel, 2023-2032

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. Online Pharmacy

11.1.2.1. Market Revenue and Forecast (2021-2032)

11.1.3. Retail Pharmacy

11.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Pharmacogenomics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2021-2032)

12.1.2. Market Revenue and Forecast, by Applications (2021-2032)

12.1.3. Market Revenue and Forecast, by End User (2021-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.1.5.2. Market Revenue and Forecast, by Applications (2021-2032)

12.1.5.3. Market Revenue and Forecast, by End User (2021-2032)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.1.6.2. Market Revenue and Forecast, by Applications (2021-2032)

12.1.6.3. Market Revenue and Forecast, by End User (2021-2032)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.2. Market Revenue and Forecast, by Applications (2021-2032)

12.2.3. Market Revenue and Forecast, by End User (2021-2032)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.5.2. Market Revenue and Forecast, by Applications (2021-2032)

12.2.5.3. Market Revenue and Forecast, by End User (2021-2032)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.6.2. Market Revenue and Forecast, by Applications (2021-2032)

12.2.6.3. Market Revenue and Forecast, by End User (2021-2032)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.7.2. Market Revenue and Forecast, by Applications (2021-2032)

12.2.7.3. Market Revenue and Forecast, by End User (2021-2032)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.8.2. Market Revenue and Forecast, by Applications (2021-2032)

12.2.8.3. Market Revenue and Forecast, by End User (2021-2032)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.2. Market Revenue and Forecast, by Applications (2021-2032)

12.3.3. Market Revenue and Forecast, by End User (2021-2032)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.5.2. Market Revenue and Forecast, by Applications (2021-2032)

12.3.5.3. Market Revenue and Forecast, by End User (2021-2032)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.6.2. Market Revenue and Forecast, by Applications (2021-2032)

12.3.6.3. Market Revenue and Forecast, by End User (2021-2032)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.7.2. Market Revenue and Forecast, by Applications (2021-2032)

12.3.7.3. Market Revenue and Forecast, by End User (2021-2032)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.8.2. Market Revenue and Forecast, by Applications (2021-2032)

12.3.8.3. Market Revenue and Forecast, by End User (2021-2032)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.2. Market Revenue and Forecast, by Applications (2021-2032)

12.4.3. Market Revenue and Forecast, by End User (2021-2032)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.5.2. Market Revenue and Forecast, by Applications (2021-2032)

12.4.5.3. Market Revenue and Forecast, by End User (2021-2032)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.6.2. Market Revenue and Forecast, by Applications (2021-2032)

12.4.6.3. Market Revenue and Forecast, by End User (2021-2032)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.7.2. Market Revenue and Forecast, by Applications (2021-2032)

12.4.7.3. Market Revenue and Forecast, by End User (2021-2032)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.8.2. Market Revenue and Forecast, by Applications (2021-2032)

12.4.8.3. Market Revenue and Forecast, by End User (2021-2032)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.5.2. Market Revenue and Forecast, by Applications (2021-2032)

12.5.3. Market Revenue and Forecast, by End User (2021-2032)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.5.5.2. Market Revenue and Forecast, by Applications (2021-2032)

12.5.5.3. Market Revenue and Forecast, by End User (2021-2032)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.5.6.2. Market Revenue and Forecast, by Applications (2021-2032)

12.5.6.3. Market Revenue and Forecast, by End User (2021-2032)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

Chapter 13. Company Profiles

13.1. Abbott (US)

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bayer AG (Germany)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Allergan (Ireland)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. AbbVie Inc (US)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GmBH (Germany)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Teva Pharmaceutical Industries ltd (India)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Natco Pharma Limited (India)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Lupin (India)

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sun Pharmaceutical Industries ltd (India)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Merck & Co Inc (Germany)

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert